Literature DB >> 11939409

Mutation and functional analysis of IL-13 receptors in human malignant glioma cells.

M Kawakami1, P Leland, K Kawakami, R K Puri.   

Abstract

We have previously demonstrated that human brain tumor cells, in particular glioblastoma multiforme (GBM), express abundant receptors for interleukin-13 on the cell surface. These receptors are composed of IL-13 receptor (IL-13R)alpha1, IL-13Ralpha2, and IL-4Ralpha chains. The significance of overexpression of IL-13R on tumor cells is not known. Because expression of IL-13R on glioma cells is an unexpected phenomenon, we examined whether these receptors are polymorphic. Therefore, we analyzed cDNA for IL-13Ralpha1 and IL-13Ralpha2 chain genes by PCR-based single-strand conformation polymorphism and direct sequencing techniques for a possible polymorphism in 19 GBM, one normal human astrocyte, and two fibroblast cell lines. All analyzed samples except normal astrocytes overexpressed IL-13Ralpha2; however, none of these cell lines showed a mutation in cDNA for IL-13Ralpha2 chain. In contrast, all GBM samples, normal astrocytes, and fibroblasts expressed mRNA for IL-13Ralpha1 with apparent single nucleotide polymorphism in the transmembrane domain. To study the function of IL-13R on brain tumor cells, we investigated the regulation of adhesion molecules by IL-13 as assessed by flow cytometric analysis. A172 cell line expressed a low level of vascular cell adhesion molecule-1 (VCAM-1), while U251 and LA1-5g cell lines expressed intercellular adhesion molecule-1 (ICAM-1). On the other hand E-selectin was not expressed in any cell lines. Interestingly, IL-13 increased the expression level of VCAM-1 in A172 cell line in a dose- and time-dependent manner. However, IL-13 did not modulate any other adhesion molecules. These results suggest that IL-13R on GBM cells are not rearranged but appear to be functional.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11939409     DOI: 10.3727/096504001108747468

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  9 in total

1.  Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.

Authors:  Larisa J Geskin; Sara Viragova; Donna B Stolz; Patrizia Fuschiotti
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

2.  Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

Authors:  Seogkyoung Kong; Sadhak Sengupta; Betty Tyler; Anthony J Bais; Qiangzhong Ma; Saryn Doucette; Jinyuan Zhou; Ayguen Sahin; Bob S Carter; Henry Brem; Richard P Junghans; Prakash Sampath
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

3.  Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

Authors:  Bharat H Joshi; Rada A Puri; Pamela Leland; Frederick Varricchio; Ghanshyam Gupta; Mehmet Kocak; Richard J Gilbertson; Raj K Puri
Journal:  Neuro Oncol       Date:  2008-04-22       Impact factor: 12.300

Review 4.  Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Authors:  Syed R Husain; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

5.  Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Authors:  Ian M Zitron; Archana Thakur; Oxana Norkina; Geoffrey R Barger; Lawrence G Lum; Sandeep Mittal
Journal:  BMC Cancer       Date:  2013-02-22       Impact factor: 4.430

Review 6.  Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

Authors:  Christopher Jackson; Jacob Ruzevick; Jillian Phallen; Zineb Belcaid; Michael Lim
Journal:  Clin Dev Immunol       Date:  2011-12-10

7.  Age-related comparisons of evolution of the inflammatory response after intracerebral hemorrhage in rats.

Authors:  Starlee Lively; Lyanne C Schlichter
Journal:  Transl Stroke Res       Date:  2012-03-16       Impact factor: 6.829

Review 8.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

9.  Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization.

Authors:  Huile Gao; Zhi Yang; Shuang Zhang; Shijie Cao; Shun Shen; Zhiqing Pang; Xinguo Jiang
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.